{"ID": "DDI-DrugBank.d481.s0.p0", "TEXT1": "Milk, milk products, and @DRUG$-rich foods or drugs may impair the absorption of @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["calcium", "drug", "25-31"], "DRUGB": ["EMCYT", "brand", "82-86"]}
{"ID": "DDI-DrugBank.d419.s0.p0", "TEXT1": "The concurrent administration of @DRUG$ and @DRUG$ increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "LBL": "DDI-effect", "DRUGA": ["allopurinol", "drug", "33-43"], "DRUGB": ["ampicillin", "drug", "49-58"]}
{"ID": "DDI-DrugBank.d419.s0.p1", "TEXT1": "The concurrent administration of @DRUG$ and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving @DRUG$ alone.", "LBL": "0", "DRUGA": ["allopurinol", "drug", "33-43"], "DRUGB": ["ampicillin", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d419.s0.p2", "TEXT1": "The concurrent administration of allopurinol and @DRUG$ increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving @DRUG$ alone.", "LBL": "0", "DRUGA": ["ampicillin", "drug", "49-58"], "DRUGB": ["ampicillin", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d419.s1.p0", "TEXT1": "It is not known whether this potentiation of @DRUG$ rashes is due to @DRUG$ or the hyperuricemia present in these patients.", "LBL": "DDI-effect", "DRUGA": ["ampicillin", "drug", "45-54"], "DRUGB": ["allopurinol", "drug", "73-83"]}
{"ID": "DDI-DrugBank.d419.s2.p0", "TEXT1": "In controlled clinical trials of @DRUG$, 22 patients received concomitant @DRUG$ and AUGMENTIN XR.", "LBL": "0", "DRUGA": ["AUGMENTIN XR", "brand", "33-44"], "DRUGB": ["allopurinol", "drug", "80-90"]}
{"ID": "DDI-DrugBank.d419.s2.p1", "TEXT1": "In controlled clinical trials of @DRUG$, 22 patients received concomitant allopurinol and @DRUG$.", "LBL": "0", "DRUGA": ["AUGMENTIN XR", "brand", "33-44"], "DRUGB": ["AUGMENTIN XR", "brand", "96-107"]}
{"ID": "DDI-DrugBank.d419.s2.p2", "TEXT1": "In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["allopurinol", "drug", "80-90"], "DRUGB": ["AUGMENTIN XR", "brand", "96-107"]}
{"ID": "DDI-DrugBank.d419.s4.p0", "TEXT1": "However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant @DRUG$ and @DRUG$ use.", "LBL": "0", "DRUGA": ["AUGMENTIN XR", "brand", "126-137"], "DRUGB": ["allopurinol", "drug", "143-153"]}
{"ID": "DDI-DrugBank.d419.s5.p0", "TEXT1": "In common with other @DRUG$, @DRUG$ may reduce the efficacy of oral contraceptives", "LBL": "0", "DRUGA": ["broad-spectrum antibiotics", "group", "21-46"], "DRUGB": ["AUGMENTIN XR", "brand", "49-60"]}
{"ID": "DDI-DrugBank.d419.s5.p1", "TEXT1": "In common with other @DRUG$, AUGMENTIN XR may reduce the efficacy of oral @DRUG$", "LBL": "DDI-effect", "DRUGA": ["broad-spectrum antibiotics", "group", "21-46"], "DRUGB": ["contraceptives", "group", "94-107"]}
{"ID": "DDI-DrugBank.d419.s5.p2", "TEXT1": "In common with other broad-spectrum antibiotics, @DRUG$ may reduce the efficacy of oral @DRUG$", "LBL": "DDI-effect", "DRUGA": ["AUGMENTIN XR", "brand", "49-60"], "DRUGB": ["contraceptives", "group", "94-107"]}
{"ID": "DDI-DrugBank.d234.s0.p0", "TEXT1": "Interaction with @DRUG$ other than @DRUG$ has not been specifically studied;", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "17-50"], "DRUGB": ["benzodiazepines", "group", "63-77"]}
{"ID": "DDI-DrugBank.d234.s1.p0", "TEXT1": "however, no deleterious interactions were seen when @DRUG$ was administered after @DRUG$, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "52-60"], "DRUGB": ["narcotics", "group", "85-93"]}
{"ID": "DDI-DrugBank.d234.s1.p1", "TEXT1": "however, no deleterious interactions were seen when @DRUG$ was administered after narcotics, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "52-60"], "DRUGB": ["anesthetics", "group", "109-119"]}
{"ID": "DDI-DrugBank.d234.s1.p2", "TEXT1": "however, no deleterious interactions were seen when @DRUG$ was administered after narcotics, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "52-60"], "DRUGB": ["muscle relaxants", "group", "122-137"]}
{"ID": "DDI-DrugBank.d234.s1.p3", "TEXT1": "however, no deleterious interactions were seen when ROMAZICON was administered after @DRUG$, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["narcotics", "group", "85-93"], "DRUGB": ["anesthetics", "group", "109-119"]}
{"ID": "DDI-DrugBank.d234.s1.p4", "TEXT1": "however, no deleterious interactions were seen when ROMAZICON was administered after @DRUG$, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["narcotics", "group", "85-93"], "DRUGB": ["muscle relaxants", "group", "122-137"]}
{"ID": "DDI-DrugBank.d234.s1.p5", "TEXT1": "however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational @DRUG$, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "LBL": "0", "DRUGA": ["anesthetics", "group", "109-119"], "DRUGB": ["muscle relaxants", "group", "122-137"]}
{"ID": "DDI-DrugBank.d234.s2.p0", "TEXT1": "Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the benzodiazepine effect by flumazenil.", "LBL": "DDI-effect", "DRUGA": ["ROMAZICON", "brand", "43-51"], "DRUGB": ["cyclic antidepressants", "group", "203-224"]}
{"ID": "DDI-DrugBank.d234.s2.p1", "TEXT1": "Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the @DRUG$ effect by flumazenil.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "43-51"], "DRUGB": ["benzodiazepine", "group", "263-276"]}
{"ID": "DDI-DrugBank.d234.s2.p2", "TEXT1": "Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by @DRUG$.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "43-51"], "DRUGB": ["flumazenil", "drug", "288-297"]}
{"ID": "DDI-DrugBank.d234.s2.p3", "TEXT1": "Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the @DRUG$ effect by flumazenil.", "LBL": "0", "DRUGA": ["cyclic antidepressants", "group", "203-224"], "DRUGB": ["benzodiazepine", "group", "263-276"]}
{"ID": "DDI-DrugBank.d234.s2.p4", "TEXT1": "Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the benzodiazepine effect by @DRUG$.", "LBL": "0", "DRUGA": ["cyclic antidepressants", "group", "203-224"], "DRUGB": ["flumazenil", "drug", "288-297"]}
{"ID": "DDI-DrugBank.d234.s2.p5", "TEXT1": "Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the @DRUG$ effect by @DRUG$.", "LBL": "0", "DRUGA": ["benzodiazepine", "group", "263-276"], "DRUGB": ["flumazenil", "drug", "288-297"]}
{"ID": "DDI-DrugBank.d234.s4.p0", "TEXT1": "Although @DRUG$ exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a @DRUG$ agonist can give rise to convulsions in epileptic patients.", "LBL": "DDI-effect", "DRUGA": ["ROMAZICON", "brand", "9-17"], "DRUGB": ["benzodiazepine", "group", "121-134"]}
{"ID": "DDI-DrugBank.d234.s5.p0", "TEXT1": "@DRUG$ blocks the central effects of @DRUG$ by competitive interaction at the receptor level.", "LBL": "DDI-effect", "DRUGA": ["ROMAZICON", "brand", "0-8"], "DRUGB": ["benzodiazepines", "group", "40-54"]}
{"ID": "DDI-DrugBank.d234.s6.p0", "TEXT1": "The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as @DRUG$, triazolopyridazines and others, are also blocked by @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["zopiclone", "drug", "79-87"], "DRUGB": ["ROMAZICON", "brand", "142-150"]}
{"ID": "DDI-DrugBank.d234.s7.p0", "TEXT1": "The pharmacokinetics of @DRUG$ are unaltered in the presence of @DRUG$ and vice versa.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "24-38"], "DRUGB": ["flumazenil", "drug", "73-82"]}
{"ID": "DDI-DrugBank.d234.s8.p0", "TEXT1": "There is no pharmacokinetic interaction between @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["ethanol", "drug", "48-54"], "DRUGB": ["flumazenil", "drug", "60-69"]}
{"ID": "DDI-DrugBank.d234.s9.p0", "TEXT1": "Use in Ambulatory Patients The effects of @DRUG$ may wear off before a @DRUG$ is completely cleared from the body.", "LBL": "0", "DRUGA": ["ROMAZICON", "brand", "42-50"], "DRUGB": ["long-acting benzodiazepine", "group", "74-99"]}
{"ID": "DDI-DrugBank.d234.s11.p0", "TEXT1": "An adequate period of observation must be provided for any patient in whom either @DRUG$ (such as @DRUG$) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam) have been used.", "LBL": "0", "DRUGA": ["long-acting benzodiazepines", "group", "82-108"], "DRUGB": ["diazepam", "drug", "119-126"]}
{"ID": "DDI-DrugBank.d234.s11.p1", "TEXT1": "An adequate period of observation must be provided for any patient in whom either @DRUG$ (such as diazepam) or large doses of @DRUG$ (such as  10 mg of midazolam) have been used.", "LBL": "0", "DRUGA": ["long-acting benzodiazepines", "group", "82-108"], "DRUGB": ["short-acting benzodiazepines", "group", "147-174"]}
{"ID": "DDI-DrugBank.d234.s11.p2", "TEXT1": "An adequate period of observation must be provided for any patient in whom either @DRUG$ (such as diazepam) or large doses of short-acting benzodiazepines (such as  10 mg of @DRUG$) have been used.", "LBL": "0", "DRUGA": ["long-acting benzodiazepines", "group", "82-108"], "DRUGB": ["midazolam", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d234.s11.p3", "TEXT1": "An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as @DRUG$) or large doses of @DRUG$ (such as  10 mg of midazolam) have been used.", "LBL": "0", "DRUGA": ["diazepam", "drug", "119-126"], "DRUGB": ["short-acting benzodiazepines", "group", "147-174"]}
{"ID": "DDI-DrugBank.d234.s11.p4", "TEXT1": "An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as @DRUG$) or large doses of short-acting benzodiazepines (such as  10 mg of @DRUG$) have been used.", "LBL": "0", "DRUGA": ["diazepam", "drug", "119-126"], "DRUGB": ["midazolam", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d234.s11.p5", "TEXT1": "An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of @DRUG$ (such as  10 mg of @DRUG$) have been used.", "LBL": "0", "DRUGA": ["short-acting benzodiazepines", "group", "147-174"], "DRUGB": ["midazolam", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d234.s12.p0", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "84-98"], "DRUGB": ["benzodiazepine", "group", "215-228"]}
{"ID": "DDI-DrugBank.d234.s12.p1", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "84-98"], "DRUGB": ["alcohol", "drug", "231-237"]}
{"ID": "DDI-DrugBank.d234.s12.p2", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "84-98"], "DRUGB": ["sedative", "group", "243-250"]}
{"ID": "DDI-DrugBank.d234.s12.p3", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "84-98"], "DRUGB": ["ROMAZICON", "brand", "322-330"]}
{"ID": "DDI-DrugBank.d234.s12.p4", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["benzodiazepine", "group", "215-228"], "DRUGB": ["alcohol", "drug", "231-237"]}
{"ID": "DDI-DrugBank.d234.s12.p5", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["benzodiazepine", "group", "215-228"], "DRUGB": ["sedative", "group", "243-250"]}
{"ID": "DDI-DrugBank.d234.s12.p6", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.", "LBL": "0", "DRUGA": ["benzodiazepine", "group", "215-228"], "DRUGB": ["ROMAZICON", "brand", "322-330"]}
{"ID": "DDI-DrugBank.d234.s12.p7", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "LBL": "0", "DRUGA": ["alcohol", "drug", "231-237"], "DRUGB": ["sedative", "group", "243-250"]}
{"ID": "DDI-DrugBank.d234.s12.p8", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.", "LBL": "0", "DRUGA": ["alcohol", "drug", "231-237"], "DRUGB": ["ROMAZICON", "brand", "322-330"]}
{"ID": "DDI-DrugBank.d234.s12.p9", "TEXT1": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of @DRUG$ is planned.", "LBL": "0", "DRUGA": ["sedative", "group", "243-250"], "DRUGB": ["ROMAZICON", "brand", "322-330"]}
{"ID": "DDI-DrugBank.d470.s1.p0", "TEXT1": "Caution is advised when @DRUG$ is coadministered with other medications that can prolong the QT interval (e.g. certain @DRUG$ or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "LBL": "DDI-advise", "DRUGA": ["TRISENOX", "brand", "24-31"], "DRUGB": ["antiarrhythmics", "group", "121-135"]}
{"ID": "DDI-DrugBank.d470.s1.p1", "TEXT1": "Caution is advised when @DRUG$ is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or @DRUG$) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "LBL": "DDI-advise", "DRUGA": ["TRISENOX", "brand", "24-31"], "DRUGB": ["thioridazine", "drug", "140-151"]}
{"ID": "DDI-DrugBank.d470.s1.p2", "TEXT1": "Caution is advised when @DRUG$ is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as @DRUG$ or amphotericin B).", "LBL": "DDI-advise", "DRUGA": ["TRISENOX", "brand", "24-31"], "DRUGB": ["diuretics", "group", "200-208"]}
{"ID": "DDI-DrugBank.d470.s1.p3", "TEXT1": "Caution is advised when @DRUG$ is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or @DRUG$).", "LBL": "DDI-advise", "DRUGA": ["TRISENOX", "brand", "24-31"], "DRUGB": ["amphotericin B", "drug", "213-226"]}
{"ID": "DDI-DrugBank.d470.s1.p4", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain @DRUG$ or @DRUG$) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "LBL": "0", "DRUGA": ["antiarrhythmics", "group", "121-135"], "DRUGB": ["thioridazine", "drug", "140-151"]}
{"ID": "DDI-DrugBank.d470.s1.p5", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain @DRUG$ or thioridazine) or lead to electrolyte abnormalities (such as @DRUG$ or amphotericin B).", "LBL": "0", "DRUGA": ["antiarrhythmics", "group", "121-135"], "DRUGB": ["diuretics", "group", "200-208"]}
{"ID": "DDI-DrugBank.d470.s1.p6", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain @DRUG$ or thioridazine) or lead to electrolyte abnormalities (such as diuretics or @DRUG$).", "LBL": "0", "DRUGA": ["antiarrhythmics", "group", "121-135"], "DRUGB": ["amphotericin B", "drug", "213-226"]}
{"ID": "DDI-DrugBank.d470.s1.p7", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or @DRUG$) or lead to electrolyte abnormalities (such as @DRUG$ or amphotericin B).", "LBL": "0", "DRUGA": ["thioridazine", "drug", "140-151"], "DRUGB": ["diuretics", "group", "200-208"]}
{"ID": "DDI-DrugBank.d470.s1.p8", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or @DRUG$) or lead to electrolyte abnormalities (such as diuretics or @DRUG$).", "LBL": "0", "DRUGA": ["thioridazine", "drug", "140-151"], "DRUGB": ["amphotericin B", "drug", "213-226"]}
{"ID": "DDI-DrugBank.d470.s1.p9", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as @DRUG$ or @DRUG$).", "LBL": "0", "DRUGA": ["diuretics", "group", "200-208"], "DRUGB": ["amphotericin B", "drug", "213-226"]}
{"ID": "DDI-DrugBank.d278.s0.p0", "TEXT1": "@DRUG$ dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of @DRUG$ or the level of platelet aggregation in healthy adults.", "LBL": "0", "DRUGA": ["Enoxaparin", "drug", "0-9"], "DRUGB": ["eptifibatide", "drug", "113-124"]}
{"ID": "DDI-DrugBank.d526.s1.p0", "TEXT1": "@DRUG$ or @DRUG$ (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["Amphotericin B", "drug", "0-13"], "DRUGB": ["potassium-depleting diuretics", "group", "18-46"]}
{"ID": "DDI-DrugBank.d526.s1.p1", "TEXT1": "@DRUG$ or potassium-depleting diuretics (@DRUG$ and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["Amphotericin B", "drug", "0-13"], "DRUGB": ["benzothiadiazines", "group", "49-65"]}
{"ID": "DDI-DrugBank.d526.s1.p2", "TEXT1": "@DRUG$ or potassium-depleting diuretics (benzothiadiazines and related drugs, @DRUG$ and furosemide) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["Amphotericin B", "drug", "0-13"], "DRUGB": ["ethacrynic acid", "drug", "86-100"]}
{"ID": "DDI-DrugBank.d526.s1.p3", "TEXT1": "@DRUG$ or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and @DRUG$) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["Amphotericin B", "drug", "0-13"], "DRUGB": ["furosemide", "drug", "106-115"]}
{"ID": "DDI-DrugBank.d526.s1.p4", "TEXT1": "Amphotericin B or @DRUG$ (@DRUG$ and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["potassium-depleting diuretics", "group", "18-46"], "DRUGB": ["benzothiadiazines", "group", "49-65"]}
{"ID": "DDI-DrugBank.d526.s1.p5", "TEXT1": "Amphotericin B or @DRUG$ (benzothiadiazines and related drugs, @DRUG$ and furosemide) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["potassium-depleting diuretics", "group", "18-46"], "DRUGB": ["ethacrynic acid", "drug", "86-100"]}
{"ID": "DDI-DrugBank.d526.s1.p6", "TEXT1": "Amphotericin B or @DRUG$ (benzothiadiazines and related drugs, ethacrynic acid and @DRUG$) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["potassium-depleting diuretics", "group", "18-46"], "DRUGB": ["furosemide", "drug", "106-115"]}
{"ID": "DDI-DrugBank.d526.s1.p7", "TEXT1": "Amphotericin B or potassium-depleting diuretics (@DRUG$ and related drugs, @DRUG$ and furosemide) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["benzothiadiazines", "group", "49-65"], "DRUGB": ["ethacrynic acid", "drug", "86-100"]}
{"ID": "DDI-DrugBank.d526.s1.p8", "TEXT1": "Amphotericin B or potassium-depleting diuretics (@DRUG$ and related drugs, ethacrynic acid and @DRUG$) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["benzothiadiazines", "group", "49-65"], "DRUGB": ["furosemide", "drug", "106-115"]}
{"ID": "DDI-DrugBank.d526.s1.p9", "TEXT1": "Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, @DRUG$ and @DRUG$) enhanced hypokalemia.", "LBL": "0", "DRUGA": ["ethacrynic acid", "drug", "86-100"], "DRUGB": ["furosemide", "drug", "106-115"]}
{"ID": "DDI-DrugBank.d526.s4.p0", "TEXT1": "@DRUG$ enhanced possibility of arrhythmias or @DRUG$ toxicity associated with hypokalemia.", "LBL": "0", "DRUGA": ["Digitalis glycosides", "group", "0-19"], "DRUGB": ["digitalis", "group", "60-68"]}
{"ID": "DDI-DrugBank.d526.s9.p0", "TEXT1": "@DRUG$ (oral agents and @DRUG$) diminished antidiabetic effect.", "LBL": "0", "DRUGA": ["Antidiabetic drugs", "group", "0-17"], "DRUGB": ["insulin", "drug", "36-42"]}
{"ID": "DDI-DrugBank.d526.s14.p0", "TEXT1": "Rarely @DRUG$ toxicity may occur in patients who discontinue @DRUG$ after concurrent high-dose aspirin therapy.", "LBL": "0", "DRUGA": ["salicylate", "group", "7-16"], "DRUGB": ["steroids", "group", "65-72"]}
{"ID": "DDI-DrugBank.d526.s14.p1", "TEXT1": "Rarely @DRUG$ toxicity may occur in patients who discontinue steroids after concurrent high-dose @DRUG$ therapy.", "LBL": "0", "DRUGA": ["salicylate", "group", "7-16"], "DRUGB": ["aspirin", "brand", "101-107"]}
{"ID": "DDI-DrugBank.d526.s14.p2", "TEXT1": "Rarely salicylate toxicity may occur in patients who discontinue @DRUG$ after concurrent high-dose @DRUG$ therapy.", "LBL": "DDI-effect", "DRUGA": ["steroids", "group", "65-72"], "DRUGB": ["aspirin", "brand", "101-107"]}
{"ID": "DDI-DrugBank.d526.s15.p0", "TEXT1": "Monitor @DRUG$ levels or the therapeutic effect for which @DRUG$ is given;", "LBL": "0", "DRUGA": ["salicylate", "group", "8-17"], "DRUGB": ["aspirin", "brand", "62-68"]}
{"ID": "DDI-DrugBank.d526.s17.p0", "TEXT1": "@DRUG$, @DRUG$, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.", "LBL": "0", "DRUGA": ["Barbiturates", "group", "0-11"], "DRUGB": ["phenytoin", "drug", "14-22"]}
{"ID": "DDI-DrugBank.d526.s17.p1", "TEXT1": "@DRUG$, phenytoin, or @DRUG$ increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.", "LBL": "0", "DRUGA": ["Barbiturates", "group", "0-11"], "DRUGB": ["rifampin", "drug", "28-35"]}
{"ID": "DDI-DrugBank.d526.s17.p2", "TEXT1": "@DRUG$, phenytoin, or rifampin increased metabolic clearance of @DRUG$ because of the induction of hepatic enzymes.", "LBL": "DDI-mechanism", "DRUGA": ["Barbiturates", "group", "0-11"], "DRUGB": ["fludrocortisone acetate", "drug", "70-92"]}
{"ID": "DDI-DrugBank.d526.s17.p3", "TEXT1": "Barbiturates, @DRUG$, or @DRUG$ increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "14-22"], "DRUGB": ["rifampin", "drug", "28-35"]}
{"ID": "DDI-DrugBank.d526.s17.p4", "TEXT1": "Barbiturates, @DRUG$, or rifampin increased metabolic clearance of @DRUG$ because of the induction of hepatic enzymes.", "LBL": "DDI-mechanism", "DRUGA": ["phenytoin", "drug", "14-22"], "DRUGB": ["fludrocortisone acetate", "drug", "70-92"]}
{"ID": "DDI-DrugBank.d526.s17.p5", "TEXT1": "Barbiturates, phenytoin, or @DRUG$ increased metabolic clearance of @DRUG$ because of the induction of hepatic enzymes.", "LBL": "DDI-mechanism", "DRUGA": ["rifampin", "drug", "28-35"], "DRUGB": ["fludrocortisone acetate", "drug", "70-92"]}
{"ID": "DDI-DrugBank.d526.s18.p0", "TEXT1": "Observe the patient for possible diminished effect of @DRUG$ and increase the @DRUG$ dosage accordingly.", "LBL": "0", "DRUGA": ["steroid", "group", "54-60"], "DRUGB": ["steroid", "group", "79-85"]}
{"ID": "DDI-DrugBank.d526.s19.p0", "TEXT1": "@DRUG$ (particularly C-17 alkylated @DRUG$ such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["Anabolic steroids", "group", "0-16"], "DRUGB": ["androgens", "group", "47-55"]}
{"ID": "DDI-DrugBank.d526.s19.p1", "TEXT1": "@DRUG$ (particularly C-17 alkylated androgens such as @DRUG$, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["Anabolic steroids", "group", "0-16"], "DRUGB": ["oxymetholone", "drug", "65-76"]}
{"ID": "DDI-DrugBank.d526.s19.p2", "TEXT1": "@DRUG$ (particularly C-17 alkylated androgens such as oxymetholone, @DRUG$, norethandrolone, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["Anabolic steroids", "group", "0-16"], "DRUGB": ["methandrostenolone", "drug", "79-96"]}
{"ID": "DDI-DrugBank.d526.s19.p3", "TEXT1": "@DRUG$ (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, @DRUG$, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["Anabolic steroids", "group", "0-16"], "DRUGB": ["norethandrolone", "drug", "99-113"]}
{"ID": "DDI-DrugBank.d526.s19.p4", "TEXT1": "Anabolic steroids (particularly C-17 alkylated @DRUG$ such as @DRUG$, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["androgens", "group", "47-55"], "DRUGB": ["oxymetholone", "drug", "65-76"]}
{"ID": "DDI-DrugBank.d526.s19.p5", "TEXT1": "Anabolic steroids (particularly C-17 alkylated @DRUG$ such as oxymetholone, @DRUG$, norethandrolone, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["androgens", "group", "47-55"], "DRUGB": ["methandrostenolone", "drug", "79-96"]}
{"ID": "DDI-DrugBank.d526.s19.p6", "TEXT1": "Anabolic steroids (particularly C-17 alkylated @DRUG$ such as oxymetholone, methandrostenolone, @DRUG$, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["androgens", "group", "47-55"], "DRUGB": ["norethandrolone", "drug", "99-113"]}
{"ID": "DDI-DrugBank.d526.s19.p7", "TEXT1": "Anabolic steroids (particularly C-17 alkylated androgens such as @DRUG$, @DRUG$, norethandrolone, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["oxymetholone", "drug", "65-76"], "DRUGB": ["methandrostenolone", "drug", "79-96"]}
{"ID": "DDI-DrugBank.d526.s19.p8", "TEXT1": "Anabolic steroids (particularly C-17 alkylated androgens such as @DRUG$, methandrostenolone, @DRUG$, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["oxymetholone", "drug", "65-76"], "DRUGB": ["norethandrolone", "drug", "99-113"]}
{"ID": "DDI-DrugBank.d526.s19.p9", "TEXT1": "Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, @DRUG$, @DRUG$, and similar compounds) enhanced tendency toward edema.", "LBL": "0", "DRUGA": ["methandrostenolone", "drug", "79-96"], "DRUGB": ["norethandrolone", "drug", "99-113"]}
{"ID": "DDI-DrugBank.d526.s24.p0", "TEXT1": "When @DRUG$ therapy is initiated, a reduction in @DRUG$ dosage may be required, and increased amounts may be required when estrogen is terminated.", "LBL": "0", "DRUGA": ["estrogen", "group", "5-12"], "DRUGB": ["corticosteroid", "group", "51-64"]}
{"ID": "DDI-DrugBank.d526.s24.p1", "TEXT1": "When @DRUG$ therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when @DRUG$ is terminated.", "LBL": "0", "DRUGA": ["estrogen", "group", "5-12"], "DRUGB": ["estrogen", "group", "133-140"]}
{"ID": "DDI-DrugBank.d526.s24.p2", "TEXT1": "When estrogen therapy is initiated, a reduction in @DRUG$ dosage may be required, and increased amounts may be required when @DRUG$ is terminated.", "LBL": "0", "DRUGA": ["corticosteroid", "group", "51-64"], "DRUGB": ["estrogen", "group", "133-140"]}
{"ID": "DDI-DrugBank.d181.s0.p0", "TEXT1": "@DRUG$ or other @DRUG$ (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;", "LBL": "0", "DRUGA": ["Oxytocin", "drug", "0-7"], "DRUGB": ["oxytocics", "group", "18-26"]}
{"ID": "DDI-DrugBank.d181.s0.p1", "TEXT1": "@DRUG$ or other oxytocics (concurrent use with @DRUG$ may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;", "LBL": "DDI-effect", "DRUGA": ["Oxytocin", "drug", "0-7"], "DRUGB": ["dinoprost", "drug", "49-57"]}
{"ID": "DDI-DrugBank.d181.s0.p2", "TEXT1": "Oxytocin or other @DRUG$ (concurrent use with @DRUG$ may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;", "LBL": "DDI-effect", "DRUGA": ["oxytocics", "group", "18-26"], "DRUGB": ["dinoprost", "drug", "49-57"]}
{"ID": "DDI-DrugBank.d187.s2.p0", "TEXT1": "@DRUG$: A report of severe @DRUG$ toxicity was reported in a patient receiving Isoniazid.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "0-12"], "DRUGB": ["acetaminophen", "drug", "34-46"]}
{"ID": "DDI-DrugBank.d187.s2.p1", "TEXT1": "@DRUG$: A report of severe acetaminophen toxicity was reported in a patient receiving @DRUG$.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "0-12"], "DRUGB": ["Isoniazid", "drug", "93-101"]}
{"ID": "DDI-DrugBank.d187.s2.p2", "TEXT1": "Acetaminophen: A report of severe @DRUG$ toxicity was reported in a patient receiving @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["acetaminophen", "drug", "34-46"], "DRUGB": ["Isoniazid", "drug", "93-101"]}
{"ID": "DDI-DrugBank.d187.s3.p0", "TEXT1": "It is believed that the toxicity may have resulted from a previously unrecognized interaction between @DRUG$ and @DRUG$ and a molecular basis for this interaction has been proposed.", "LBL": "DDI-effect", "DRUGA": ["isoniazid", "drug", "102-110"], "DRUGB": ["acetaminophen", "drug", "116-128"]}
{"ID": "DDI-DrugBank.d187.s5.p0", "TEXT1": "Furthermore it has been proposed that @DRUG$ resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested @DRUG$ being converted to the toxic metabolites.", "LBL": "DDI-mechanism", "DRUGA": ["isoniazid", "drug", "38-46"], "DRUGB": ["acetaminophen", "drug", "170-182"]}
{"ID": "DDI-DrugBank.d187.s7.p0", "TEXT1": "@DRUG$: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["Isoniazid", "drug", "15-23"]}
{"ID": "DDI-DrugBank.d187.s7.p1", "TEXT1": "@DRUG$: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["carbamazepine", "drug", "60-72"]}
{"ID": "DDI-DrugBank.d187.s7.p2", "TEXT1": "@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["Carbamazepine", "drug", "104-116"]}
{"ID": "DDI-DrugBank.d187.s7.p3", "TEXT1": "@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["isoniazid", "drug", "186-194"]}
{"ID": "DDI-DrugBank.d187.s7.p4", "TEXT1": "@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p5", "TEXT1": "@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "0-12"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p6", "TEXT1": "Carbamazepine: @DRUG$ is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "DDI-mechanism", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["carbamazepine", "drug", "60-72"]}
{"ID": "DDI-DrugBank.d187.s7.p7", "TEXT1": "Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["Carbamazepine", "drug", "104-116"]}
{"ID": "DDI-DrugBank.d187.s7.p8", "TEXT1": "Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["isoniazid", "drug", "186-194"]}
{"ID": "DDI-DrugBank.d187.s7.p9", "TEXT1": "Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p10", "TEXT1": "Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.", "LBL": "0", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p11", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "60-72"], "DRUGB": ["Carbamazepine", "drug", "104-116"]}
{"ID": "DDI-DrugBank.d187.s7.p12", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "60-72"], "DRUGB": ["isoniazid", "drug", "186-194"]}
{"ID": "DDI-DrugBank.d187.s7.p13", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "60-72"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p14", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "60-72"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p15", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "DDI-advise", "DRUGA": ["Carbamazepine", "drug", "104-116"], "DRUGB": ["isoniazid", "drug", "186-194"]}
{"ID": "DDI-DrugBank.d187.s7.p16", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "104-116"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p17", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "104-116"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p18", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "186-194"], "DRUGB": ["carbamazepine", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d187.s7.p19", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "186-194"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s7.p20", "TEXT1": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "219-231"], "DRUGB": ["anticonvulsant", "group", "312-325"]}
{"ID": "DDI-DrugBank.d187.s8.p0", "TEXT1": "@DRUG$: Potential interaction of @DRUG$ and Isoniazid may exist.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["Ketoconazole", "drug", "39-50"]}
{"ID": "DDI-DrugBank.d187.s8.p1", "TEXT1": "@DRUG$: Potential interaction of Ketoconazole and @DRUG$ may exist.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["Isoniazid", "drug", "56-64"]}
{"ID": "DDI-DrugBank.d187.s8.p2", "TEXT1": "Ketoconazole: Potential interaction of @DRUG$ and @DRUG$ may exist.", "LBL": "DDI-int", "DRUGA": ["Ketoconazole", "drug", "39-50"], "DRUGB": ["Isoniazid", "drug", "56-64"]}
{"ID": "DDI-DrugBank.d187.s9.p0", "TEXT1": "@DRUG$: @DRUG$ may increase serum levels of phenytoin.", "LBL": "0", "DRUGA": ["Phenytoin", "drug", "0-8"], "DRUGB": ["Isoniazid", "drug", "11-19"]}
{"ID": "DDI-DrugBank.d187.s9.p1", "TEXT1": "@DRUG$: Isoniazid may increase serum levels of @DRUG$.", "LBL": "0", "DRUGA": ["Phenytoin", "drug", "0-8"], "DRUGB": ["phenytoin", "drug", "50-58"]}
{"ID": "DDI-DrugBank.d187.s9.p2", "TEXT1": "Phenytoin: @DRUG$ may increase serum levels of @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["Isoniazid", "drug", "11-19"], "DRUGB": ["phenytoin", "drug", "50-58"]}
{"ID": "DDI-DrugBank.d187.s10.p0", "TEXT1": "To avoid @DRUG$ intoxication, appropriate adjustment of the @DRUG$ should be made.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "9-17"], "DRUGB": ["anticonvulsant", "group", "63-76"]}
{"ID": "DDI-DrugBank.d187.s11.p0", "TEXT1": "Therophylline: A recent study has shown that concomitan administration of @DRUG$ and @DRUG$ may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.", "LBL": "DDI-mechanism", "DRUGA": ["isoniazid", "drug", "74-82"], "DRUGB": ["theophylline", "drug", "88-99"]}
{"ID": "DDI-DrugBank.d187.s11.p1", "TEXT1": "Therophylline: A recent study has shown that concomitan administration of @DRUG$ and theophylline may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of isoniazid.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "74-82"], "DRUGB": ["theophylline", "drug", "137-148"]}
{"ID": "DDI-DrugBank.d187.s11.p2", "TEXT1": "Therophylline: A recent study has shown that concomitan administration of @DRUG$ and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of @DRUG$.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "74-82"], "DRUGB": ["isoniazid", "drug", "213-221"]}
{"ID": "DDI-DrugBank.d187.s11.p3", "TEXT1": "Therophylline: A recent study has shown that concomitan administration of isoniazid and @DRUG$ may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of isoniazid.", "LBL": "0", "DRUGA": ["theophylline", "drug", "88-99"], "DRUGB": ["theophylline", "drug", "137-148"]}
{"ID": "DDI-DrugBank.d187.s11.p4", "TEXT1": "Therophylline: A recent study has shown that concomitan administration of isoniazid and @DRUG$ may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of @DRUG$.", "LBL": "0", "DRUGA": ["theophylline", "drug", "88-99"], "DRUGB": ["isoniazid", "drug", "213-221"]}
{"ID": "DDI-DrugBank.d187.s11.p5", "TEXT1": "Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of @DRUG$.", "LBL": "0", "DRUGA": ["theophylline", "drug", "137-148"], "DRUGB": ["isoniazid", "drug", "213-221"]}
{"ID": "DDI-DrugBank.d187.s12.p0", "TEXT1": "Since the therapeutic range of @DRUG$ is narrow @DRUG$ serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.", "LBL": "0", "DRUGA": ["theophylline", "drug", "31-42"], "DRUGB": ["theophylline", "drug", "54-65"]}
{"ID": "DDI-DrugBank.d187.s12.p1", "TEXT1": "Since the therapeutic range of @DRUG$ is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of @DRUG$ should be made.", "LBL": "0", "DRUGA": ["theophylline", "drug", "31-42"], "DRUGB": ["theophylline", "drug", "147-158"]}
{"ID": "DDI-DrugBank.d187.s12.p2", "TEXT1": "Since the therapeutic range of theophylline is narrow @DRUG$ serum levels should be monitored closely, and appropriate dosage adjustments of @DRUG$ should be made.", "LBL": "0", "DRUGA": ["theophylline", "drug", "54-65"], "DRUGB": ["theophylline", "drug", "147-158"]}
{"ID": "DDI-DrugBank.d187.s13.p0", "TEXT1": "@DRUG$: A recent case study has shown a possible increase in the plasma level of @DRUG$ when co administered with isoniazid.", "LBL": "0", "DRUGA": ["Valproate", "drug", "0-8"], "DRUGB": ["valproate", "drug", "84-92"]}
{"ID": "DDI-DrugBank.d187.s13.p1", "TEXT1": "@DRUG$: A recent case study has shown a possible increase in the plasma level of valproate when co administered with @DRUG$.", "LBL": "0", "DRUGA": ["Valproate", "drug", "0-8"], "DRUGB": ["isoniazid", "drug", "120-128"]}
{"ID": "DDI-DrugBank.d187.s13.p2", "TEXT1": "Valproate: A recent case study has shown a possible increase in the plasma level of @DRUG$ when co administered with @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["valproate", "drug", "84-92"], "DRUGB": ["isoniazid", "drug", "120-128"]}
{"ID": "DDI-DrugBank.d187.s14.p0", "TEXT1": "Plasma @DRUG$ concentration should be monitored when @DRUG$ and valproate are co administered, and appropriate dosage adjustments of valproate should be made.", "LBL": "0", "DRUGA": ["valproate", "drug", "7-15"], "DRUGB": ["isoniazid", "drug", "56-64"]}
{"ID": "DDI-DrugBank.d187.s14.p1", "TEXT1": "Plasma @DRUG$ concentration should be monitored when isoniazid and @DRUG$ are co administered, and appropriate dosage adjustments of valproate should be made.", "LBL": "0", "DRUGA": ["valproate", "drug", "7-15"], "DRUGB": ["valproate", "drug", "70-78"]}
{"ID": "DDI-DrugBank.d187.s14.p2", "TEXT1": "Plasma @DRUG$ concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of @DRUG$ should be made.", "LBL": "0", "DRUGA": ["valproate", "drug", "7-15"], "DRUGB": ["valproate", "drug", "139-147"]}
{"ID": "DDI-DrugBank.d187.s14.p3", "TEXT1": "Plasma valproate concentration should be monitored when @DRUG$ and @DRUG$ are co administered, and appropriate dosage adjustments of valproate should be made.", "LBL": "DDI-advise", "DRUGA": ["isoniazid", "drug", "56-64"], "DRUGB": ["valproate", "drug", "70-78"]}
{"ID": "DDI-DrugBank.d187.s14.p4", "TEXT1": "Plasma valproate concentration should be monitored when @DRUG$ and valproate are co administered, and appropriate dosage adjustments of @DRUG$ should be made.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "56-64"], "DRUGB": ["valproate", "drug", "139-147"]}
{"ID": "DDI-DrugBank.d187.s14.p5", "TEXT1": "Plasma valproate concentration should be monitored when isoniazid and @DRUG$ are co administered, and appropriate dosage adjustments of @DRUG$ should be made.", "LBL": "0", "DRUGA": ["valproate", "drug", "70-78"], "DRUGB": ["valproate", "drug", "139-147"]}
{"ID": "DDI-DrugBank.d323.s0.p0", "TEXT1": "Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "LBL": "DDI-advise", "DRUGA": ["MYOBLOC", "brand", "21-27"], "DRUGB": ["aminoglycosides", "group", "33-47"]}
{"ID": "DDI-DrugBank.d323.s0.p1", "TEXT1": "Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.", "LBL": "DDI-advise", "DRUGA": ["MYOBLOC", "brand", "21-27"], "DRUGB": ["curare-like compounds", "group", "116-136"]}
{"ID": "DDI-DrugBank.d323.s0.p2", "TEXT1": "Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.", "LBL": "0", "DRUGA": ["MYOBLOC", "brand", "21-27"], "DRUGB": ["toxin", "drug", "198-202"]}
{"ID": "DDI-DrugBank.d323.s0.p3", "TEXT1": "Co-administration of MYOBLOC and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "33-47"], "DRUGB": ["curare-like compounds", "group", "116-136"]}
{"ID": "DDI-DrugBank.d323.s0.p4", "TEXT1": "Co-administration of MYOBLOC and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "33-47"], "DRUGB": ["toxin", "drug", "198-202"]}
{"ID": "DDI-DrugBank.d323.s0.p5", "TEXT1": "Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the @DRUG$ may be potentiated.", "LBL": "0", "DRUGA": ["curare-like compounds", "group", "116-136"], "DRUGB": ["toxin", "drug", "198-202"]}
{"ID": "DDI-DrugBank.d289.s6.p0", "TEXT1": "@DRUG$, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["Contraceptives", "group", "82-95"]}
{"ID": "DDI-DrugBank.d289.s6.p1", "TEXT1": "@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["bosentan", "drug", "158-165"]}
{"ID": "DDI-DrugBank.d289.s6.p2", "TEXT1": "@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["hormonal contraceptive", "group", "180-201"]}
{"ID": "DDI-DrugBank.d289.s6.p3", "TEXT1": "@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["Ortho-Novum", "brand", "203-213"]}
{"ID": "DDI-DrugBank.d289.s6.p4", "TEXT1": "@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p5", "TEXT1": "@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Hormonal Contraceptives", "group", "0-22"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p6", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["bosentan", "drug", "158-165"]}
{"ID": "DDI-DrugBank.d289.s6.p7", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["hormonal contraceptive", "group", "180-201"]}
{"ID": "DDI-DrugBank.d289.s6.p8", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["Ortho-Novum", "brand", "203-213"]}
{"ID": "DDI-DrugBank.d289.s6.p9", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p10", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "82-95"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p11", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["bosentan", "drug", "158-165"], "DRUGB": ["hormonal contraceptive", "group", "180-201"]}
{"ID": "DDI-DrugBank.d289.s6.p12", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "158-165"], "DRUGB": ["Ortho-Novum", "brand", "203-213"]}
{"ID": "DDI-DrugBank.d289.s6.p13", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["bosentan", "drug", "158-165"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p14", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["bosentan", "drug", "158-165"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p15", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["hormonal contraceptive", "group", "180-201"], "DRUGB": ["Ortho-Novum", "brand", "203-213"]}
{"ID": "DDI-DrugBank.d289.s6.p16", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["hormonal contraceptive", "group", "180-201"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p17", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["hormonal contraceptive", "group", "180-201"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p18", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Ortho-Novum", "brand", "203-213"], "DRUGB": ["norethindrone", "drug", "245-257"]}
{"ID": "DDI-DrugBank.d289.s6.p19", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["Ortho-Novum", "brand", "203-213"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s6.p20", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and @DRUG$ levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["norethindrone", "drug", "245-257"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d289.s8.p0", "TEXT1": "Therefore, @DRUG$, including oral, injectable, transdermal, and implantable forms, may not be reliable when @DRUG$ is co-administered.", "LBL": "DDI-effect", "DRUGA": ["hormonal contraceptives", "group", "11-33"], "DRUGB": ["TRACLEER", "brand", "125-132"]}
{"ID": "DDI-DrugBank.d289.s10.p0", "TEXT1": "Specific interaction studies have demonstrated the following: @DRUG$: During the first day of concomitant administration, trough concentrations of @DRUG$ were increased by about 30-fold.", "LBL": "0", "DRUGA": ["Cyclosporine A", "drug", "62-75"], "DRUGB": ["bosentan", "drug", "155-162"]}
{"ID": "DDI-DrugBank.d289.s11.p0", "TEXT1": "Steady-state @DRUG$ plasma concentrations were 3- to 4-fold higher than in the absence of @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "13-20"], "DRUGB": ["cyclosporine A", "drug", "92-105"]}
{"ID": "DDI-DrugBank.d289.s12.p0", "TEXT1": "The concomitant administration of @DRUG$ and @DRUG$ is contraindicated.", "LBL": "DDI-advise", "DRUGA": ["bosentan", "drug", "34-41"], "DRUGB": ["cyclosporine A", "drug", "47-60"]}
{"ID": "DDI-DrugBank.d289.s13.p0", "TEXT1": "Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate) by approximately 50%.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "21-28"], "DRUGB": ["cyclosporine A", "drug", "69-82"]}
{"ID": "DDI-DrugBank.d289.s14.p0", "TEXT1": "@DRUG$: Co-administration of @DRUG$ and bosentan has not been studied in man.", "LBL": "0", "DRUGA": ["Tacrolimus", "drug", "0-9"], "DRUGB": ["tacrolimus", "drug", "33-42"]}
{"ID": "DDI-DrugBank.d289.s14.p1", "TEXT1": "@DRUG$: Co-administration of tacrolimus and @DRUG$ has not been studied in man.", "LBL": "0", "DRUGA": ["Tacrolimus", "drug", "0-9"], "DRUGB": ["bosentan", "drug", "48-55"]}
{"ID": "DDI-DrugBank.d289.s14.p2", "TEXT1": "Tacrolimus: Co-administration of @DRUG$ and @DRUG$ has not been studied in man.", "LBL": "0", "DRUGA": ["tacrolimus", "drug", "33-42"], "DRUGB": ["bosentan", "drug", "48-55"]}
{"ID": "DDI-DrugBank.d289.s15.p0", "TEXT1": "Co-administration of @DRUG$ and @DRUG$ resulted in markedly increased plasma concentrations of bosentan in animals.", "LBL": "DDI-mechanism", "DRUGA": ["tacrolimus", "drug", "21-30"], "DRUGB": ["bosentan", "drug", "36-43"]}
{"ID": "DDI-DrugBank.d289.s15.p1", "TEXT1": "Co-administration of @DRUG$ and bosentan resulted in markedly increased plasma concentrations of @DRUG$ in animals.", "LBL": "0", "DRUGA": ["tacrolimus", "drug", "21-30"], "DRUGB": ["bosentan", "drug", "101-108"]}
{"ID": "DDI-DrugBank.d289.s15.p2", "TEXT1": "Co-administration of tacrolimus and @DRUG$ resulted in markedly increased plasma concentrations of @DRUG$ in animals.", "LBL": "0", "DRUGA": ["bosentan", "drug", "36-43"], "DRUGB": ["bosentan", "drug", "101-108"]}
{"ID": "DDI-DrugBank.d289.s16.p0", "TEXT1": "Caution should be exercised if @DRUG$ and @DRUG$ are used together.", "LBL": "DDI-advise", "DRUGA": ["tacrolimus", "drug", "31-40"], "DRUGB": ["bosentan", "drug", "46-53"]}
{"ID": "DDI-DrugBank.d289.s17.p0", "TEXT1": "@DRUG$: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with @DRUG$.", "LBL": "0", "DRUGA": ["Glyburide", "drug", "0-8"], "DRUGB": ["glyburide", "drug", "125-133"]}
{"ID": "DDI-DrugBank.d289.s18.p0", "TEXT1": "Therefore, the concomitant administration of @DRUG$ and @DRUG$ is contraindicated, and alternative hypoglycemic agents should be considered.", "LBL": "DDI-advise", "DRUGA": ["TRACLEER", "brand", "45-52"], "DRUGB": ["glyburide", "drug", "58-66"]}
{"ID": "DDI-DrugBank.d289.s18.p1", "TEXT1": "Therefore, the concomitant administration of @DRUG$ and glyburide is contraindicated, and alternative @DRUG$ should be considered.", "LBL": "0", "DRUGA": ["TRACLEER", "brand", "45-52"], "DRUGB": ["hypoglycemic agents", "group", "104-122"]}
{"ID": "DDI-DrugBank.d289.s18.p2", "TEXT1": "Therefore, the concomitant administration of TRACLEER and @DRUG$ is contraindicated, and alternative @DRUG$ should be considered.", "LBL": "0", "DRUGA": ["glyburide", "drug", "58-66"], "DRUGB": ["hypoglycemic agents", "group", "104-122"]}
{"ID": "DDI-DrugBank.d289.s19.p0", "TEXT1": "Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ by approximately 40%.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "21-28"], "DRUGB": ["glyburide", "drug", "69-77"]}
{"ID": "DDI-DrugBank.d289.s21.p0", "TEXT1": "@DRUG$ is also expected to reduce plasma concentrations of other oral @DRUG$ that are predominantly metabolized by CYP2C9 or CYP3A4.", "LBL": "DDI-mechanism", "DRUGA": ["Bosentan", "drug", "0-7"], "DRUGB": ["hypoglycemic agents", "group", "72-90"]}
{"ID": "DDI-DrugBank.d289.s23.p0", "TEXT1": "@DRUG$: Co-administration of @DRUG$ 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["bosentan", "drug", "35-42"]}
{"ID": "DDI-DrugBank.d289.s23.p1", "TEXT1": "@DRUG$: Co-administration of bosentan 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["ketoconazole", "drug", "62-73"]}
{"ID": "DDI-DrugBank.d289.s23.p2", "TEXT1": "@DRUG$: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.", "LBL": "0", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["bosentan", "drug", "142-149"]}
{"ID": "DDI-DrugBank.d289.s23.p3", "TEXT1": "Ketoconazole: Co-administration of @DRUG$ 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "35-42"], "DRUGB": ["ketoconazole", "drug", "62-73"]}
{"ID": "DDI-DrugBank.d289.s23.p4", "TEXT1": "Ketoconazole: Co-administration of @DRUG$ 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.", "LBL": "0", "DRUGA": ["bosentan", "drug", "35-42"], "DRUGB": ["bosentan", "drug", "142-149"]}
{"ID": "DDI-DrugBank.d289.s23.p5", "TEXT1": "Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "62-73"], "DRUGB": ["bosentan", "drug", "142-149"]}
{"ID": "DDI-DrugBank.d289.s24.p0", "TEXT1": "No dose adjustment of @DRUG$ is necessary, but increased effects of @DRUG$ should be considered.", "LBL": "0", "DRUGA": ["bosentan", "drug", "22-29"], "DRUGB": ["bosentan", "drug", "70-77"]}
{"ID": "DDI-DrugBank.d289.s25.p0", "TEXT1": "@DRUG$ and Other @DRUG$: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.", "LBL": "0", "DRUGA": ["Simvastatin", "drug", "0-10"], "DRUGB": ["Statins", "group", "22-28"]}
{"ID": "DDI-DrugBank.d289.s25.p1", "TEXT1": "@DRUG$ and Other Statins: Co-administration of @DRUG$ decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.", "LBL": "0", "DRUGA": ["Simvastatin", "drug", "0-10"], "DRUGB": ["bosentan", "drug", "52-59"]}
{"ID": "DDI-DrugBank.d289.s25.p2", "TEXT1": "@DRUG$ and Other Statins: Co-administration of bosentan decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.", "LBL": "0", "DRUGA": ["Simvastatin", "drug", "0-10"], "DRUGB": ["simvastatin", "drug", "100-110"]}
{"ID": "DDI-DrugBank.d289.s25.p3", "TEXT1": "Simvastatin and Other @DRUG$: Co-administration of @DRUG$ decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.", "LBL": "0", "DRUGA": ["Statins", "group", "22-28"], "DRUGB": ["bosentan", "drug", "52-59"]}
{"ID": "DDI-DrugBank.d289.s25.p4", "TEXT1": "Simvastatin and Other @DRUG$: Co-administration of bosentan decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.", "LBL": "0", "DRUGA": ["Statins", "group", "22-28"], "DRUGB": ["simvastatin", "drug", "100-110"]}
{"ID": "DDI-DrugBank.d289.s25.p5", "TEXT1": "Simvastatin and Other Statins: Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "52-59"], "DRUGB": ["simvastatin", "drug", "100-110"]}
{"ID": "DDI-DrugBank.d289.s27.p0", "TEXT1": "@DRUG$ is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.", "LBL": "DDI-mechanism", "DRUGA": ["Bosentan", "drug", "0-7"], "DRUGB": ["statins", "group", "67-73"]}
{"ID": "DDI-DrugBank.d289.s27.p1", "TEXT1": "@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and atorvastatin.", "LBL": "DDI-mechanism", "DRUGA": ["Bosentan", "drug", "0-7"], "DRUGB": ["lovastatin", "drug", "127-136"]}
{"ID": "DDI-DrugBank.d289.s27.p2", "TEXT1": "@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["Bosentan", "drug", "0-7"], "DRUGB": ["atorvastatin", "drug", "142-153"]}
{"ID": "DDI-DrugBank.d289.s27.p3", "TEXT1": "Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as @DRUG$ and atorvastatin.", "LBL": "0", "DRUGA": ["statins", "group", "67-73"], "DRUGB": ["lovastatin", "drug", "127-136"]}
{"ID": "DDI-DrugBank.d289.s27.p4", "TEXT1": "Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.", "LBL": "0", "DRUGA": ["statins", "group", "67-73"], "DRUGB": ["atorvastatin", "drug", "142-153"]}
{"ID": "DDI-DrugBank.d289.s27.p5", "TEXT1": "Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["lovastatin", "drug", "127-136"], "DRUGB": ["atorvastatin", "drug", "142-153"]}
{"ID": "DDI-DrugBank.d289.s29.p0", "TEXT1": "Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after @DRUG$ is initiated to see whether the statin dose needs adjustment.", "LBL": "DDI-advise", "DRUGA": ["statins", "group", "34-40"], "DRUGB": ["TRACLEER", "brand", "89-96"]}
{"ID": "DDI-DrugBank.d289.s29.p1", "TEXT1": "Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after TRACLEER is initiated to see whether the @DRUG$ dose needs adjustment.", "LBL": "0", "DRUGA": ["statins", "group", "34-40"], "DRUGB": ["statin", "group", "130-135"]}
{"ID": "DDI-DrugBank.d289.s29.p2", "TEXT1": "Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after @DRUG$ is initiated to see whether the @DRUG$ dose needs adjustment.", "LBL": "0", "DRUGA": ["TRACLEER", "brand", "89-96"], "DRUGB": ["statin", "group", "130-135"]}
{"ID": "DDI-DrugBank.d289.s30.p0", "TEXT1": "@DRUG$: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.", "LBL": "0", "DRUGA": ["Warfarin", "drug", "0-7"], "DRUGB": ["bosentan", "drug", "31-38"]}
{"ID": "DDI-DrugBank.d289.s30.p1", "TEXT1": "@DRUG$: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.", "LBL": "0", "DRUGA": ["Warfarin", "drug", "0-7"], "DRUGB": ["S-warfarin", "drug", "109-118"]}
{"ID": "DDI-DrugBank.d289.s30.p2", "TEXT1": "@DRUG$: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.", "LBL": "0", "DRUGA": ["Warfarin", "drug", "0-7"], "DRUGB": ["R-warfarin", "drug", "145-154"]}
{"ID": "DDI-DrugBank.d289.s30.p3", "TEXT1": "Warfarin: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "31-38"], "DRUGB": ["S-warfarin", "drug", "109-118"]}
{"ID": "DDI-DrugBank.d289.s30.p4", "TEXT1": "Warfarin: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.", "LBL": "DDI-mechanism", "DRUGA": ["bosentan", "drug", "31-38"], "DRUGB": ["R-warfarin", "drug", "145-154"]}
{"ID": "DDI-DrugBank.d289.s30.p5", "TEXT1": "Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.", "LBL": "0", "DRUGA": ["S-warfarin", "drug", "109-118"], "DRUGB": ["R-warfarin", "drug", "145-154"]}
{"ID": "DDI-DrugBank.d289.s31.p0", "TEXT1": "Clinical experience with concomitant administration of @DRUG$ and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["bosentan", "drug", "55-62"], "DRUGB": ["warfarin", "drug", "68-75"]}
{"ID": "DDI-DrugBank.d289.s31.p1", "TEXT1": "Clinical experience with concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["bosentan", "drug", "55-62"], "DRUGB": ["warfarin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d289.s31.p2", "TEXT1": "Clinical experience with concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["bosentan", "drug", "55-62"], "DRUGB": ["warfarin", "drug", "262-269"]}
{"ID": "DDI-DrugBank.d289.s31.p3", "TEXT1": "Clinical experience with concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.", "LBL": "0", "DRUGA": ["bosentan", "drug", "55-62"], "DRUGB": ["bosentan", "drug", "359-366"]}
{"ID": "DDI-DrugBank.d289.s31.p4", "TEXT1": "Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "68-75"], "DRUGB": ["warfarin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d289.s31.p5", "TEXT1": "Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "68-75"], "DRUGB": ["warfarin", "drug", "262-269"]}
{"ID": "DDI-DrugBank.d289.s31.p6", "TEXT1": "Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "68-75"], "DRUGB": ["bosentan", "drug", "359-366"]}
{"ID": "DDI-DrugBank.d289.s31.p7", "TEXT1": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "177-184"], "DRUGB": ["warfarin", "drug", "262-269"]}
{"ID": "DDI-DrugBank.d289.s31.p8", "TEXT1": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "177-184"], "DRUGB": ["bosentan", "drug", "359-366"]}
{"ID": "DDI-DrugBank.d289.s31.p9", "TEXT1": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.", "LBL": "0", "DRUGA": ["warfarin", "drug", "262-269"], "DRUGB": ["bosentan", "drug", "359-366"]}
{"ID": "DDI-DrugBank.d289.s32.p0", "TEXT1": "@DRUG$, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["Nimodipine", "drug", "9-18"]}
{"ID": "DDI-DrugBank.d289.s32.p1", "TEXT1": "@DRUG$, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["Losartan", "drug", "24-31"]}
{"ID": "DDI-DrugBank.d289.s32.p2", "TEXT1": "@DRUG$, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["Bosentan", "drug", "34-41"]}
{"ID": "DDI-DrugBank.d289.s32.p3", "TEXT1": "@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["digoxin", "drug", "96-102"]}
{"ID": "DDI-DrugBank.d289.s32.p4", "TEXT1": "@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p5", "TEXT1": "@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p6", "TEXT1": "@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p7", "TEXT1": "Digoxin, @DRUG$ and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["Losartan", "drug", "24-31"]}
{"ID": "DDI-DrugBank.d289.s32.p8", "TEXT1": "Digoxin, @DRUG$ and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["Bosentan", "drug", "34-41"]}
{"ID": "DDI-DrugBank.d289.s32.p9", "TEXT1": "Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["digoxin", "drug", "96-102"]}
{"ID": "DDI-DrugBank.d289.s32.p10", "TEXT1": "Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p11", "TEXT1": "Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p12", "TEXT1": "Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["Nimodipine", "drug", "9-18"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p13", "TEXT1": "Digoxin, Nimodipine and @DRUG$: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["Bosentan", "drug", "34-41"]}
{"ID": "DDI-DrugBank.d289.s32.p14", "TEXT1": "Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["digoxin", "drug", "96-102"]}
{"ID": "DDI-DrugBank.d289.s32.p15", "TEXT1": "Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p16", "TEXT1": "Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p17", "TEXT1": "Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["Losartan", "drug", "24-31"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p18", "TEXT1": "Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Bosentan", "drug", "34-41"], "DRUGB": ["digoxin", "drug", "96-102"]}
{"ID": "DDI-DrugBank.d289.s32.p19", "TEXT1": "Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Bosentan", "drug", "34-41"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p20", "TEXT1": "Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["Bosentan", "drug", "34-41"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p21", "TEXT1": "Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["Bosentan", "drug", "34-41"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p22", "TEXT1": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["digoxin", "drug", "96-102"], "DRUGB": ["nimodipine", "drug", "108-117"]}
{"ID": "DDI-DrugBank.d289.s32.p23", "TEXT1": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["digoxin", "drug", "96-102"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p24", "TEXT1": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["digoxin", "drug", "96-102"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p25", "TEXT1": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and @DRUG$ has no significant effect on plasma levels of bosentan.", "LBL": "0", "DRUGA": ["nimodipine", "drug", "108-117"], "DRUGB": ["losartan", "drug", "124-131"]}
{"ID": "DDI-DrugBank.d289.s32.p26", "TEXT1": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["nimodipine", "drug", "108-117"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d289.s32.p27", "TEXT1": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of @DRUG$.", "LBL": "0", "DRUGA": ["losartan", "drug", "124-131"], "DRUGB": ["bosentan", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d5.s0.p0", "TEXT1": "Few systemic data have been collected on the metabolism of @DRUG$ following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of @DRUG$ on the metabolism of other drugs.", "LBL": "0", "DRUGA": ["WELLBUTRIN", "brand", "59-68"], "DRUGB": ["WELLBUTRIN", "brand", "187-196"]}
{"ID": "DDI-DrugBank.d5.s2.p0", "TEXT1": "In vitro studies indicate that @DRUG$ is primarily metabolized to @DRUG$ by the CYP2B6 isoenzyme.", "LBL": "0", "DRUGA": ["bupropion", "drug", "31-39"], "DRUGB": ["hydroxybupropion", "drug_n", "69-84"]}
{"ID": "DDI-DrugBank.d5.s3.p0", "TEXT1": "Therefore, the potential exists for a drug interaction between @DRUG$ and drugs that affect the CYP2B6 isoenzyme (e.g., @DRUG$ and cyclophosphamide).", "LBL": "DDI-int", "DRUGA": ["WELLBUTRIN", "brand", "63-72"], "DRUGB": ["orphenadrine", "drug", "124-135"]}
{"ID": "DDI-DrugBank.d5.s3.p1", "TEXT1": "Therefore, the potential exists for a drug interaction between @DRUG$ and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and @DRUG$).", "LBL": "DDI-int", "DRUGA": ["WELLBUTRIN", "brand", "63-72"], "DRUGB": ["cyclophosphamide", "drug", "141-156"]}
{"ID": "DDI-DrugBank.d5.s3.p2", "TEXT1": "Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., @DRUG$ and @DRUG$).", "LBL": "0", "DRUGA": ["orphenadrine", "drug", "124-135"], "DRUGB": ["cyclophosphamide", "drug", "141-156"]}
{"ID": "DDI-DrugBank.d5.s4.p0", "TEXT1": "The @DRUG$ metabolite of @DRUG$ does not appear to be produced by the cytochrome P450 isoenzymes.", "LBL": "0", "DRUGA": ["threohydrobupropion", "drug_n", "4-22"], "DRUGB": ["bupropion", "drug", "38-46"]}
{"ID": "DDI-DrugBank.d5.s5.p0", "TEXT1": "The effects of concomitant administration of @DRUG$ on the pharmacokinetics of @DRUG$ and its active metabolites were studied in 24 healthy young male volunteers.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "45-54"], "DRUGB": ["bupropion", "drug", "83-91"]}
{"ID": "DDI-DrugBank.d5.s6.p0", "TEXT1": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of @DRUG$, the pharmacokinetics of @DRUG$ and hydroxybupropion were unaffected.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "97-106"], "DRUGB": ["bupropion", "drug", "133-141"]}
{"ID": "DDI-DrugBank.d5.s6.p1", "TEXT1": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of @DRUG$, the pharmacokinetics of bupropion and @DRUG$ were unaffected.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "97-106"], "DRUGB": ["hydroxybupropion", "drug_n", "147-162"]}
{"ID": "DDI-DrugBank.d5.s6.p2", "TEXT1": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of @DRUG$ and @DRUG$ were unaffected.", "LBL": "0", "DRUGA": ["bupropion", "drug", "133-141"], "DRUGB": ["hydroxybupropion", "drug_n", "147-162"]}
{"ID": "DDI-DrugBank.d5.s7.p0", "TEXT1": "However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["threohydrobupropion", "drug_n", "105-123"], "DRUGB": ["erythrohydrobupropion", "drug_n", "129-149"]}
{"ID": "DDI-DrugBank.d5.s8.p0", "TEXT1": "While not systematically studied, certain drugs may induce the metabolism of @DRUG$ (e.g., @DRUG$, phenobarbital, phenytoin).", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "77-85"], "DRUGB": ["carbamazepine", "drug", "94-106"]}
{"ID": "DDI-DrugBank.d5.s8.p1", "TEXT1": "While not systematically studied, certain drugs may induce the metabolism of @DRUG$ (e.g., carbamazepine, @DRUG$, phenytoin).", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "77-85"], "DRUGB": ["phenobarbital", "drug", "109-121"]}
{"ID": "DDI-DrugBank.d5.s8.p2", "TEXT1": "While not systematically studied, certain drugs may induce the metabolism of @DRUG$ (e.g., carbamazepine, phenobarbital, @DRUG$).", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "77-85"], "DRUGB": ["phenytoin", "drug", "124-132"]}
{"ID": "DDI-DrugBank.d5.s8.p3", "TEXT1": "While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., @DRUG$, @DRUG$, phenytoin).", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "94-106"], "DRUGB": ["phenobarbital", "drug", "109-121"]}
{"ID": "DDI-DrugBank.d5.s8.p4", "TEXT1": "While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., @DRUG$, phenobarbital, @DRUG$).", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "94-106"], "DRUGB": ["phenytoin", "drug", "124-132"]}
{"ID": "DDI-DrugBank.d5.s8.p5", "TEXT1": "While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, @DRUG$, @DRUG$).", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "109-121"], "DRUGB": ["phenytoin", "drug", "124-132"]}
{"ID": "DDI-DrugBank.d5.s12.p0", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many @DRUG$), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["antidepressants", "group", "78-92"], "DRUGB": ["tricyclics", "group", "107-116"]}
{"ID": "DDI-DrugBank.d5.s12.p1", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many tricyclics), @DRUG$, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["antidepressants", "group", "78-92"], "DRUGB": ["beta-blockers", "group", "120-132"]}
{"ID": "DDI-DrugBank.d5.s12.p2", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many tricyclics), beta-blockers, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["antidepressants", "group", "78-92"], "DRUGB": ["antiarrhythmics", "drug", "135-149"]}
{"ID": "DDI-DrugBank.d5.s12.p3", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["antidepressants", "group", "78-92"], "DRUGB": ["antipsychotics", "group", "156-169"]}
{"ID": "DDI-DrugBank.d5.s12.p4", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many @DRUG$), @DRUG$, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["tricyclics", "group", "107-116"], "DRUGB": ["beta-blockers", "group", "120-132"]}
{"ID": "DDI-DrugBank.d5.s12.p5", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many @DRUG$), beta-blockers, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["tricyclics", "group", "107-116"], "DRUGB": ["antiarrhythmics", "drug", "135-149"]}
{"ID": "DDI-DrugBank.d5.s12.p6", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many @DRUG$), beta-blockers, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["tricyclics", "group", "107-116"], "DRUGB": ["antipsychotics", "group", "156-169"]}
{"ID": "DDI-DrugBank.d5.s12.p7", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), @DRUG$, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "120-132"], "DRUGB": ["antiarrhythmics", "drug", "135-149"]}
{"ID": "DDI-DrugBank.d5.s12.p8", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), @DRUG$, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "120-132"], "DRUGB": ["antipsychotics", "group", "156-169"]}
{"ID": "DDI-DrugBank.d5.s12.p9", "TEXT1": "Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, @DRUG$, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.", "LBL": "0", "DRUGA": ["antiarrhythmics", "drug", "135-149"], "DRUGB": ["antipsychotics", "group", "156-169"]}
{"ID": "DDI-DrugBank.d5.s13.p0", "TEXT1": "Although @DRUG$ is not metabolized by this isoenzyme, @DRUG$ and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.", "LBL": "0", "DRUGA": ["bupropion", "drug", "9-17"], "DRUGB": ["bupropion", "drug", "57-65"]}
{"ID": "DDI-DrugBank.d5.s13.p1", "TEXT1": "Although @DRUG$ is not metabolized by this isoenzyme, bupropion and @DRUG$ are inhibitors of the CYP2D6 isoenzyme in vitro.", "LBL": "0", "DRUGA": ["bupropion", "drug", "9-17"], "DRUGB": ["hydroxybupropion", "drug_n", "71-86"]}
{"ID": "DDI-DrugBank.d5.s13.p2", "TEXT1": "Although bupropion is not metabolized by this isoenzyme, @DRUG$ and @DRUG$ are inhibitors of the CYP2D6 isoenzyme in vitro.", "LBL": "0", "DRUGA": ["bupropion", "drug", "57-65"], "DRUGB": ["hydroxybupropion", "drug_n", "71-86"]}
{"ID": "DDI-DrugBank.d5.s14.p0", "TEXT1": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of @DRUG$ given as 150 mg twice daily followed by a single dose of 50 mg @DRUG$ increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "125-133"], "DRUGB": ["desipramine", "drug", "198-208"]}
{"ID": "DDI-DrugBank.d5.s14.p1", "TEXT1": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of @DRUG$ given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of @DRUG$ by an average of approximately 2-, 5- and 2-fold, respectively.", "LBL": "0", "DRUGA": ["bupropion", "drug", "125-133"], "DRUGB": ["desipramine", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s14.p2", "TEXT1": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg @DRUG$ increased the Cmax, AUC, and t1/2 of @DRUG$ by an average of approximately 2-, 5- and 2-fold, respectively.", "LBL": "0", "DRUGA": ["desipramine", "drug", "198-208"], "DRUGB": ["desipramine", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p0", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["antidepressants", "group", "112-126"]}
{"ID": "DDI-DrugBank.d5.s17.p1", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["nortriptyline", "drug", "135-147"]}
{"ID": "DDI-DrugBank.d5.s17.p2", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["imipramine", "drug", "150-159"]}
{"ID": "DDI-DrugBank.d5.s17.p3", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["desipramine", "drug", "162-172"]}
{"ID": "DDI-DrugBank.d5.s17.p4", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p5", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p6", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p7", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p8", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p9", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p10", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p11", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p12", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p13", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p14", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p15", "TEXT1": "Therefore, co-administration of @DRUG$ with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "DDI-advise", "DRUGA": ["bupropion", "drug", "32-40"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p16", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["nortriptyline", "drug", "135-147"]}
{"ID": "DDI-DrugBank.d5.s17.p17", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["imipramine", "drug", "150-159"]}
{"ID": "DDI-DrugBank.d5.s17.p18", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["desipramine", "drug", "162-172"]}
{"ID": "DDI-DrugBank.d5.s17.p19", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p20", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p21", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p22", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p23", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p24", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p25", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p26", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p27", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p28", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p29", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p30", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain @DRUG$ (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antidepressants", "group", "112-126"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p31", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["imipramine", "drug", "150-159"]}
{"ID": "DDI-DrugBank.d5.s17.p32", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["desipramine", "drug", "162-172"]}
{"ID": "DDI-DrugBank.d5.s17.p33", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p34", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p35", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p36", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p37", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p38", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p39", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p40", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p41", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p42", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p43", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p44", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p45", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["desipramine", "drug", "162-172"]}
{"ID": "DDI-DrugBank.d5.s17.p46", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p47", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p48", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p49", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p50", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p51", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p52", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p53", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p54", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p55", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p56", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p57", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p58", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s17.p59", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p60", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p61", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p62", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p63", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p64", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p65", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p66", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p67", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p68", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p69", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p70", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d5.s17.p71", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p72", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p73", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p74", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p75", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p76", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p77", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p78", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p79", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p80", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "175-184"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p81", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["sertraline", "drug", "199-208"]}
{"ID": "DDI-DrugBank.d5.s17.p82", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p83", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p84", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p85", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p86", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p87", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p88", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p89", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p90", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "187-196"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p91", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["antipsychotics", "group", "212-225"]}
{"ID": "DDI-DrugBank.d5.s17.p92", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p93", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p94", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p95", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p96", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p97", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p98", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p99", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, @DRUG$), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["sertraline", "drug", "199-208"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p100", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["haloperidol", "drug", "234-244"]}
{"ID": "DDI-DrugBank.d5.s17.p101", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p102", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p103", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p104", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p105", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p106", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p107", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), @DRUG$ (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "212-225"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p108", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["risperidone", "drug", "247-257"]}
{"ID": "DDI-DrugBank.d5.s17.p109", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p110", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p111", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p112", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p113", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p114", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p115", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["thioridazine", "drug", "260-271"]}
{"ID": "DDI-DrugBank.d5.s17.p116", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p117", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p118", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p119", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p120", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, @DRUG$, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["risperidone", "drug", "247-257"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p121", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d5.s17.p122", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p123", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p124", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p125", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, @DRUG$), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["thioridazine", "drug", "260-271"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p126", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "275-287"], "DRUGB": ["metoprolol", "drug", "296-305"]}
{"ID": "DDI-DrugBank.d5.s17.p127", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "275-287"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p128", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "275-287"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p129", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "275-287"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p130", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and @DRUG$ (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["metoprolol", "drug", "296-305"], "DRUGB": ["Type 1C antiarrhythmics", "group", "313-335"]}
{"ID": "DDI-DrugBank.d5.s17.p131", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["metoprolol", "drug", "296-305"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p132", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., @DRUG$), and Type 1C antiarrhythmics (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["metoprolol", "drug", "296-305"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p133", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["Type 1C antiarrhythmics", "group", "313-335"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d5.s17.p134", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and @DRUG$ (e.g., propafenone, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["Type 1C antiarrhythmics", "group", "313-335"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s17.p135", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, @DRUG$), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["propafenone", "drug", "344-354"], "DRUGB": ["flecainide", "drug", "357-366"]}
{"ID": "DDI-DrugBank.d5.s19.p0", "TEXT1": "@DRUG$: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the MAO inhibitor phenelzine .", "LBL": "0", "DRUGA": ["MAO Inhibitors", "group", "0-13"], "DRUGB": ["bupropion", "drug", "74-82"]}
{"ID": "DDI-DrugBank.d5.s19.p1", "TEXT1": "@DRUG$: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the @DRUG$ phenelzine .", "LBL": "0", "DRUGA": ["MAO Inhibitors", "group", "0-13"], "DRUGB": ["MAO inhibitor", "group", "103-115"]}
{"ID": "DDI-DrugBank.d5.s19.p2", "TEXT1": "@DRUG$: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor @DRUG$ .", "LBL": "0", "DRUGA": ["MAO Inhibitors", "group", "0-13"], "DRUGB": ["phenelzine", "drug", "117-126"]}
{"ID": "DDI-DrugBank.d5.s19.p3", "TEXT1": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the @DRUG$ phenelzine .", "LBL": "0", "DRUGA": ["bupropion", "drug", "74-82"], "DRUGB": ["MAO inhibitor", "group", "103-115"]}
{"ID": "DDI-DrugBank.d5.s19.p4", "TEXT1": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the MAO inhibitor @DRUG$ .", "LBL": "DDI-effect", "DRUGA": ["bupropion", "drug", "74-82"], "DRUGB": ["phenelzine", "drug", "117-126"]}
{"ID": "DDI-DrugBank.d5.s19.p5", "TEXT1": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the @DRUG$ @DRUG$ .", "LBL": "0", "DRUGA": ["MAO inhibitor", "group", "103-115"], "DRUGB": ["phenelzine", "drug", "117-126"]}
{"ID": "DDI-DrugBank.d5.s20.p0", "TEXT1": "@DRUG$ and @DRUG$: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.", "LBL": "0", "DRUGA": ["Levodopa", "drug", "0-7"], "DRUGB": ["Amantadine", "drug", "13-22"]}
{"ID": "DDI-DrugBank.d5.s20.p1", "TEXT1": "@DRUG$ and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving @DRUG$ concurrently with either levodopa or amantadine.", "LBL": "0", "DRUGA": ["Levodopa", "drug", "0-7"], "DRUGB": ["bupropion", "drug", "119-127"]}
{"ID": "DDI-DrugBank.d5.s20.p2", "TEXT1": "@DRUG$ and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either @DRUG$ or amantadine.", "LBL": "0", "DRUGA": ["Levodopa", "drug", "0-7"], "DRUGB": ["levodopa", "drug", "154-161"]}
{"ID": "DDI-DrugBank.d5.s20.p3", "TEXT1": "@DRUG$ and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or @DRUG$.", "LBL": "0", "DRUGA": ["Levodopa", "drug", "0-7"], "DRUGB": ["amantadine", "drug", "166-175"]}
{"ID": "DDI-DrugBank.d5.s20.p4", "TEXT1": "Levodopa and @DRUG$: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving @DRUG$ concurrently with either levodopa or amantadine.", "LBL": "0", "DRUGA": ["Amantadine", "drug", "13-22"], "DRUGB": ["bupropion", "drug", "119-127"]}
{"ID": "DDI-DrugBank.d5.s20.p5", "TEXT1": "Levodopa and @DRUG$: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either @DRUG$ or amantadine.", "LBL": "0", "DRUGA": ["Amantadine", "drug", "13-22"], "DRUGB": ["levodopa", "drug", "154-161"]}
{"ID": "DDI-DrugBank.d5.s20.p6", "TEXT1": "Levodopa and @DRUG$: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or @DRUG$.", "LBL": "0", "DRUGA": ["Amantadine", "drug", "13-22"], "DRUGB": ["amantadine", "drug", "166-175"]}
{"ID": "DDI-DrugBank.d5.s20.p7", "TEXT1": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving @DRUG$ concurrently with either @DRUG$ or amantadine.", "LBL": "DDI-effect", "DRUGA": ["bupropion", "drug", "119-127"], "DRUGB": ["levodopa", "drug", "154-161"]}
{"ID": "DDI-DrugBank.d5.s20.p8", "TEXT1": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving @DRUG$ concurrently with either levodopa or @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["bupropion", "drug", "119-127"], "DRUGB": ["amantadine", "drug", "166-175"]}
{"ID": "DDI-DrugBank.d5.s20.p9", "TEXT1": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either @DRUG$ or @DRUG$.", "LBL": "0", "DRUGA": ["levodopa", "drug", "154-161"], "DRUGB": ["amantadine", "drug", "166-175"]}
{"ID": "DDI-DrugBank.d5.s21.p0", "TEXT1": "Administration of @DRUG$ Tablets to patients receiving either @DRUG$ or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "18-27"], "DRUGB": ["levodopa", "drug", "66-73"]}
{"ID": "DDI-DrugBank.d5.s21.p1", "TEXT1": "Administration of @DRUG$ Tablets to patients receiving either levodopa or @DRUG$ concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "18-27"], "DRUGB": ["amantadine", "drug", "78-87"]}
{"ID": "DDI-DrugBank.d5.s21.p2", "TEXT1": "Administration of WELLBUTRIN Tablets to patients receiving either @DRUG$ or @DRUG$ concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.", "LBL": "0", "DRUGA": ["levodopa", "drug", "66-73"], "DRUGB": ["amantadine", "drug", "78-87"]}
{"ID": "DDI-DrugBank.d5.s22.p0", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of @DRUG$ and agents (e.g., @DRUG$, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "65-74"], "DRUGB": ["antipsychotics", "group", "94-107"]}
{"ID": "DDI-DrugBank.d5.s22.p1", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of @DRUG$ and agents (e.g., antipsychotics, other @DRUG$, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "65-74"], "DRUGB": ["antidepressants", "group", "116-130"]}
{"ID": "DDI-DrugBank.d5.s22.p2", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of @DRUG$ and agents (e.g., antipsychotics, other antidepressants, @DRUG$, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "65-74"], "DRUGB": ["theophylline", "drug", "133-144"]}
{"ID": "DDI-DrugBank.d5.s22.p3", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of @DRUG$ and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic @DRUG$, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "DDI-advise", "DRUGA": ["WELLBUTRIN", "brand", "65-74"], "DRUGB": ["steroids", "group", "156-163"]}
{"ID": "DDI-DrugBank.d5.s22.p4", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., @DRUG$, other @DRUG$, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "94-107"], "DRUGB": ["antidepressants", "group", "116-130"]}
{"ID": "DDI-DrugBank.d5.s22.p5", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., @DRUG$, other antidepressants, @DRUG$, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "94-107"], "DRUGB": ["theophylline", "drug", "133-144"]}
{"ID": "DDI-DrugBank.d5.s22.p6", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., @DRUG$, other antidepressants, theophylline, systemic @DRUG$, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "0", "DRUGA": ["antipsychotics", "group", "94-107"], "DRUGB": ["steroids", "group", "156-163"]}
{"ID": "DDI-DrugBank.d5.s22.p7", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other @DRUG$, @DRUG$, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "0", "DRUGA": ["antidepressants", "group", "116-130"], "DRUGB": ["theophylline", "drug", "133-144"]}
{"ID": "DDI-DrugBank.d5.s22.p8", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other @DRUG$, theophylline, systemic @DRUG$, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "0", "DRUGA": ["antidepressants", "group", "116-130"], "DRUGB": ["steroids", "group", "156-163"]}
{"ID": "DDI-DrugBank.d5.s22.p9", "TEXT1": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, @DRUG$, systemic @DRUG$, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "LBL": "0", "DRUGA": ["theophylline", "drug", "133-144"], "DRUGB": ["steroids", "group", "156-163"]}
{"ID": "DDI-DrugBank.d5.s25.p0", "TEXT1": "@DRUG$: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced @DRUG$ tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.", "LBL": "0", "DRUGA": ["Alcohol", "drug", "0-6"], "DRUGB": ["alcohol", "drug", "114-120"]}
{"ID": "DDI-DrugBank.d5.s25.p1", "TEXT1": "@DRUG$: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking @DRUG$ during treatment with WELLBUTRIN.", "LBL": "0", "DRUGA": ["Alcohol", "drug", "0-6"], "DRUGB": ["alcohol", "drug", "162-168"]}
{"ID": "DDI-DrugBank.d5.s25.p2", "TEXT1": "@DRUG$: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with @DRUG$.", "LBL": "0", "DRUGA": ["Alcohol", "drug", "0-6"], "DRUGB": ["WELLBUTRIN", "brand", "192-201"]}
{"ID": "DDI-DrugBank.d5.s25.p3", "TEXT1": "Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced @DRUG$ tolerance in patients who were drinking @DRUG$ during treatment with WELLBUTRIN.", "LBL": "0", "DRUGA": ["alcohol", "drug", "114-120"], "DRUGB": ["alcohol", "drug", "162-168"]}
{"ID": "DDI-DrugBank.d5.s25.p4", "TEXT1": "Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced @DRUG$ tolerance in patients who were drinking alcohol during treatment with @DRUG$.", "LBL": "0", "DRUGA": ["alcohol", "drug", "114-120"], "DRUGB": ["WELLBUTRIN", "brand", "192-201"]}
{"ID": "DDI-DrugBank.d5.s25.p5", "TEXT1": "Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking @DRUG$ during treatment with @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["alcohol", "drug", "162-168"], "DRUGB": ["WELLBUTRIN", "brand", "192-201"]}
{"ID": "DDI-DrugBank.d5.s26.p0", "TEXT1": "The consumption of @DRUG$ during treatment with @DRUG$ should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)", "LBL": "DDI-advise", "DRUGA": ["alcohol", "drug", "19-25"], "DRUGB": ["WELLBUTRIN", "brand", "49-58"]}
{"ID": "DDI-DrugBank.d297.s1.p0", "TEXT1": "Population pharmacokinetic analyses revealed that @DRUG$, @DRUG$, corticosteroids, and TNF blocking agents did not influence abatacept clearance.", "LBL": "0", "DRUGA": ["MTX", "drug", "50-52"], "DRUGB": ["NSAIDs", "group", "55-60"]}
{"ID": "DDI-DrugBank.d297.s1.p1", "TEXT1": "Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, @DRUG$, and TNF blocking agents did not influence abatacept clearance.", "LBL": "0", "DRUGA": ["MTX", "drug", "50-52"], "DRUGB": ["corticosteroids", "group", "63-77"]}
{"ID": "DDI-DrugBank.d297.s1.p2", "TEXT1": "Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, corticosteroids, and @DRUG$ did not influence abatacept clearance.", "LBL": "0", "DRUGA": ["MTX", "drug", "50-52"], "DRUGB": ["TNF blocking agents", "group", "84-102"]}
{"ID": "DDI-DrugBank.d297.s1.p3", "TEXT1": "Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, corticosteroids, and TNF blocking agents did not influence @DRUG$ clearance.", "LBL": "0", "DRUGA": ["MTX", "drug", "50-52"], "DRUGB": ["abatacept", "drug", "122-130"]}
{"ID": "DDI-DrugBank.d297.s1.p4", "TEXT1": "Population pharmacokinetic analyses revealed that MTX, @DRUG$, @DRUG$, and TNF blocking agents did not influence abatacept clearance.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "55-60"], "DRUGB": ["corticosteroids", "group", "63-77"]}
{"ID": "DDI-DrugBank.d297.s1.p5", "TEXT1": "Population pharmacokinetic analyses revealed that MTX, @DRUG$, corticosteroids, and @DRUG$ did not influence abatacept clearance.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "55-60"], "DRUGB": ["TNF blocking agents", "group", "84-102"]}
{"ID": "DDI-DrugBank.d297.s1.p6", "TEXT1": "Population pharmacokinetic analyses revealed that MTX, @DRUG$, corticosteroids, and TNF blocking agents did not influence @DRUG$ clearance.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "55-60"], "DRUGB": ["abatacept", "drug", "122-130"]}
{"ID": "DDI-DrugBank.d297.s1.p7", "TEXT1": "Population pharmacokinetic analyses revealed that MTX, NSAIDs, @DRUG$, and @DRUG$ did not influence abatacept clearance.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "63-77"], "DRUGB": ["TNF blocking agents", "group", "84-102"]}
{"ID": "DDI-DrugBank.d297.s1.p8", "TEXT1": "Population pharmacokinetic analyses revealed that MTX, NSAIDs, @DRUG$, and TNF blocking agents did not influence @DRUG$ clearance.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "63-77"], "DRUGB": ["abatacept", "drug", "122-130"]}
{"ID": "DDI-DrugBank.d297.s1.p9", "TEXT1": "Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and @DRUG$ did not influence @DRUG$ clearance.", "LBL": "0", "DRUGA": ["TNF blocking agents", "group", "84-102"], "DRUGB": ["abatacept", "drug", "122-130"]}
{"ID": "DDI-DrugBank.d297.s2.p0", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["MTX", "drug", "124-126"]}
{"ID": "DDI-DrugBank.d297.s2.p1", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["NSAIDs", "group", "129-134"]}
{"ID": "DDI-DrugBank.d297.s2.p2", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["corticosteroids", "group", "137-151"]}
{"ID": "DDI-DrugBank.d297.s2.p3", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["TNF blocking agents", "group", "154-172"]}
{"ID": "DDI-DrugBank.d297.s2.p4", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["azathioprine", "drug", "175-186"]}
{"ID": "DDI-DrugBank.d297.s2.p5", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["chloroquine", "drug", "189-199"]}
{"ID": "DDI-DrugBank.d297.s2.p6", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["gold", "drug", "202-205"]}
{"ID": "DDI-DrugBank.d297.s2.p7", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["hydroxychloroquine", "drug", "208-225"]}
{"ID": "DDI-DrugBank.d297.s2.p8", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["leflunomide", "drug", "228-238"]}
{"ID": "DDI-DrugBank.d297.s2.p9", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["sulfasalazine", "drug", "241-253"]}
{"ID": "DDI-DrugBank.d297.s2.p10", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["anakinra", "drug", "260-267"]}
{"ID": "DDI-DrugBank.d297.s2.p11", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["NSAIDs", "group", "129-134"]}
{"ID": "DDI-DrugBank.d297.s2.p12", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["corticosteroids", "group", "137-151"]}
{"ID": "DDI-DrugBank.d297.s2.p13", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["TNF blocking agents", "group", "154-172"]}
{"ID": "DDI-DrugBank.d297.s2.p14", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["azathioprine", "drug", "175-186"]}
{"ID": "DDI-DrugBank.d297.s2.p15", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["chloroquine", "drug", "189-199"]}
{"ID": "DDI-DrugBank.d297.s2.p16", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["gold", "drug", "202-205"]}
{"ID": "DDI-DrugBank.d297.s2.p17", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["hydroxychloroquine", "drug", "208-225"]}
{"ID": "DDI-DrugBank.d297.s2.p18", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["leflunomide", "drug", "228-238"]}
{"ID": "DDI-DrugBank.d297.s2.p19", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["sulfasalazine", "drug", "241-253"]}
{"ID": "DDI-DrugBank.d297.s2.p20", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["anakinra", "drug", "260-267"]}
{"ID": "DDI-DrugBank.d297.s2.p21", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["corticosteroids", "group", "137-151"]}
{"ID": "DDI-DrugBank.d297.s2.p22", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["TNF blocking agents", "group", "154-172"]}
{"ID": "DDI-DrugBank.d297.s2.p23", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["azathioprine", "drug", "175-186"]}
{"ID": "DDI-DrugBank.d297.s2.p24", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["chloroquine", "drug", "189-199"]}
{"ID": "DDI-DrugBank.d297.s2.p25", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["gold", "drug", "202-205"]}
